- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
IDEXX Laboratories Inc(IDXX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for IDXX
11/13/2026: IDXX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
IDEXX Laboratories Inc is a leading global provider of diagnostic and information technology solutions for companion animals, livestock, and water quality testing. The company's primary strengths stem from an integrated ecosystem of proprietary in-clinic instruments, reference labs, and software that drives high customer retention and recurring consumable revenues. Its main growth opportunity lies in expanding international diagnostic testing penetration and integrating advanced AI workflow solutions like CoVet. However, key risks include elevated valuation multiples, reliance on discretionary pet healthcare spending, and intense competition from well-capitalized rivals. The stock best suits growth-oriented investors willing to monitor execution risks and valuation sensitivity.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | IDEXX consistently delivers double-digit revenue and earnings growth driven by secular tailwinds in pet healthcare. |
| Momentum investor | Strong fit while signal remains positive | The stock often exhibits strong multi-year momentum backed by consistent earnings beats and robust organic growth trends. |
| Value investor | Weak fit | The company trades at a premium valuation multiple that reflects its high quality and growth profile. |
| Dividend investor | Weak fit | IDEXX does not pay a regular cash dividend, focusing instead on capital reinvestment and share repurchases. |
| Low-risk investor | Mixed fit | While the business model is resilient and high quality, premium valuation multiples expose the stock to price volatility during market pullbacks. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | High growth expectations can amplify stock price swings during broader market corrections. |
| Valuation risk | High | Trading at elevated price-to-earnings multiples leaves the stock sensitive to any unexpected deceleration in growth. |
| Competition risk (Mars Petcare / Antech and Zoetis) | Medium / high | Aggressive moves by well-funded competitors could pressure market share in reference labs and diagnostics. |
| Business quality | Strong | High recurring revenue streams and entrenched customer relationships underpin exceptional franchise quality. |
| Dividend income | Low / none | Income-focused investors will find no regular dividend distributions. |
| Execution risk | Medium | Sustaining high organic growth requires continuous successful execution of new product launches and global sales initiatives. |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 55.48B USD | Price to earnings Ratio 47.45 | 1Y Target Price 717.17 |
Price to earnings Ratio 47.45 | 1Y Target Price 717.17 | ||
Volume (30-day avg) 657.9K shares | Beta 1.54 | 52 Weeks Range 500.61 - 769.98 | Updated Date 11/15/2026 |
52 Weeks Range 500.61 - 769.98 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 14.84 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Diagnostics & Research
- BUY participation
- 68.8%
- Active BUY / eligible
- 11 / 16
- 30-Day BUY Count Change
- 0
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Downtrend
The stock has experienced a sustained decline in price over recent periods.

Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 59.87% | Avg. Invested days 41 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Companion Animal Group (CAG) Diagnostics Recurring Revenue | Consumables for in-clinic analyzers, rapid test kits (SNAP), and reference laboratory diagnostic testing services. | This is the primary growth engine, generating sticky, recurring revenue every time a vet runs a test. |
| Premium Instrument Systems | Sales and placements of in-clinic diagnostic equipment such as Catalyst One, ProCyte Dx, and inVue Dx. | Placing analyzers in clinics creates a captive installed base that subsequently buys high-margin consumables. |
| Water Quality Products | Microbiological testing kits and instruments for municipal and industrial water safety compliance. | Provides a steady, defensive stream of non-veterinary revenue tied to regulatory safety testing standards. |
| Veterinary Software and Services | Cloud-based practice management software (ezyVet) and AI-enabled scribe tools (CoVet). | Deepens clinic workflow integration, increasing customer retention and ecosystem lock-in. |
| Geographic Exposure | International sales across Europe, Asia-Pacific, and the Americas alongside North America. | Offers global diversification, though foreign exchange movements can impact reported results. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-11-02 | When Before Market | Estimate 3.71 | Actual 3.98 |
Profitability
Profit Margin 25.36% | Operating Margin (TTM) 32.5% |
Management Effectiveness
Return on Assets (TTM) 26.7% | Return on Equity (TTM) 68.93% |
Valuation
Trailing PE 47.45 | Forward PE 41.49 | Enterprise Value 56.26B | Price to Sales(TTM) 11.9 |
Enterprise Value 56.26B | Price to Sales(TTM) 11.9 | ||
Enterprise Value to Revenue 12.07 | Enterprise Value to EBITDA 33.66 | Shares Outstanding 78.79M | Shares Floating 78.51M |
Shares Outstanding 78.79M | Shares Floating 78.51M | ||
Percent Insiders 0.68 | Percent Institutions 94.64 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

